On October 22, WUXI XDC fell 3.15% in Regular Trading, trading at HK$73.75, with turnover of HK$77.41 million.
Recent public information does not show a new company-specific negative catalyst, while the latest market update indicates the stock’s weakness was broadly aligned with pressure across its sector.
In the Life Sciences Tools & Services sector, peer stocks were also under pressure, including WUXI BIO falling 4.13%, WUXI APPTEC falling 1.84%, INSILICO falling 6.84%, XTALPI falling 3.11%, and GENSCRIPT B-1K falling 0.99%. Earlier disclosed interim results showed first-half revenue of RMB3.701 billion, up 37.0% year on year, and adjusted net profit of RMB1.027 billion, up 37.4%, while a prior broker note maintained a Buy rating with a HK$97.90 target price.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments